Retraction

Retraction Retraction (3094) Total Article Views Authors: Singhai R Published Date March 2012 Volume 2012:4 Pages 33 - 34 DOI: http://dx.doi.org/10.2147/BCTT.S31163 Received: 23 February 2012 Accepted: Published: 09 March 2012 The Editor-in-Chief and Publisher of Breast Cancer: Targets and Therapy have been alerted to unacceptable levels of duplication with previously published papers. All four papers were submitted by Dr Rajeev Singhai. It is worth noting that all papers were peer-reviewed by a minimum of two peer-reviewers and the Editor-in-Chief of Breast Cancer: Targets and Therapy before publication. The papers concerned are: Patil VW, Tayade MB, Pingale SA, et al. The p53 breast cancer tissue biomarker in Indian women. Breast Cancer: Targets and Therapy. 2011;3:71–78. Singhai R, Patil AV, Patil VW. Cancer biomarker HER-2/neu in breast cancer in Indian women. Breast Cancer: Targets and Therapy. 2011;3:21–26. Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW. Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women. Breast Cancer: Targets and Therapy. 2011;3:27–33. Patil VW, Singhai R, Patil AV, Gurav PD. Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Cancer: Targets and Therapy. 2011;3:9–19. Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Readers of this article also read: Alogliptin: a new addition to the class of DPP-4 inhibitors Epigenomics in cancer management Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women The p53 breast cancer tissue biomarker in Indian women A triple negative breast cancer: what it is not! The effect of nicotine on the mechanical properties of mesenchymal stem cells Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer Retraction Feasibility of abdominoplasty with Cesarean section [Retraction]